The lung endothelin system: a potent therapeutic target with bosentan for the amelioration of lung alterations in a rat model of diabetes mellitus
详细信息 查看全文
- 作者：A. Cayir ; R. A. Ugan ; A. Albayrak ; D. Kose…
- 关键词：Bosentan ; Lung injury ; Endothelin system ; Diabetes
- 刊名：Journal of Endocrinological Investigation
- 出版年：2015
- 出版时间：September 2015
- 年：2015
- 卷：38
- 期：9
- 页码：987-998
- 全文大小：
- 参考文献：1.Karalliedde J, Gnudi L (2014) Diabetes mellitus, a complex and heterogeneous disease, and the role of insulin resistance as a determinant of diabetic kidney disease. Nephrol Dial Transplant Off Publ Eur Dial Transplant Assoc Eur Renal Assoc. doi:10.鈥?093/鈥媙dt/鈥媑fu405
2.Dave S (2014) Mesenchymal stem cells derived in vitro transdifferentiated insulin-producing cells: a new approach to treat type 1 diabetes. Adv Biomed Res 3:266. doi:10.鈥?103/鈥?277-9175.鈥?48247 PubMed Central CrossRef PubMed
3.Rosenbloom AL, Silverstein JH, Amemiya S, Zeitler P, Klingensmith G (2009) Type 2 diabetes in the child and adolescent. Pediatr Diabetes 10(Suppl 12):17鈥?2. doi:10.鈥?111/鈥媕.鈥?399-448.鈥?009.鈥?0584.鈥媥 CrossRef PubMed
4.Simsek DG, Aycan Z, Ozen S, Cetinkaya S, Kara C, Abali S, Demir K, Tunc O, Ucakturk A, Asar G, Bas F, Cetinkaya E, Aydin M, Karaguzel G, Orbak Z, Siklar Z, Altincik A, Okten A, Ozkan B, Ocal G, Semiz S, Arslanoglu I, Evliyaoglu O, Bundak R, Darcan S (2013) Diabetes care, glycemic control, complications, and concomitant autoimmune diseases in children with type 1 diabetes in Turkey: a multicenter study. J Clin Res Pediatr Endocrinol 5(1):20鈥?6. doi:10.鈥?274/鈥婮crpe.鈥?93 PubMed Central CrossRef PubMed
5.Demirel F, Tepe D, Kara O, Esen I (2013) Microvascular complications in adolescents with type 1 diabetes mellitus. J Clin Res Pediatr Endocrinol 5(3):145鈥?49. doi:10.鈥?274/鈥婮crpe.鈥?94 PubMed Central CrossRef PubMed
6.Genuth S, Eastman R, Kahn R, Klein R, Lachin J, Lebovitz H, Nathan D, Vinicor F (2003) Implications of the United kingdom prospective diabetes study. Diabetes Care 26(Suppl 1):S28鈥揝32PubMed
7.Gilbert RE (2013) Endothelial loss and repair in the vascular complications of diabetes: pathogenetic mechanisms and therapeutic implications. Circ J 77(4):849鈥?56CrossRef PubMed
8.Genuth S (2006) Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes. Endocr Pract 12(Suppl 1):34鈥?1. doi:10.鈥?158/鈥婨P.鈥?2.鈥婼1.鈥?4 CrossRef PubMed
9.Kilpatrick ES, Rigby AS, Atkin SL (2009) Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Diabetes Care 32(10):1901鈥?903. doi:10.鈥?337/鈥媎c09-0109 PubMed Central CrossRef PubMed
10.Popov D, Simionescu M (2001) Structural and transport property alterations of the lung capillary endothelium in diabetes. Ital J Anat Embryol 106(2 Suppl 1):405鈥?12PubMed
11.Vojtkova J, Ciljakova M, Michnova Z, Turcan T (2012) Chronic complications of diabetes mellitus related to the respiratory system. Pediatr Endocrinol Diabetes Metab 18(3):112鈥?15PubMed
12.Weynand B, Jonckheere A, Frans A, Rahier J (1999) Diabetes mellitus induces a thickening of the pulmonary basal lamina. Respiration 66(1):14鈥?9. doi:10.鈥?159/鈥?00029331 CrossRef PubMed
13.Hsia CC, Raskin P (2007) Lung function changes related to diabetes mellitus. Diabetes Technol Ther 9(Suppl 1):S73鈥揝82. doi:10.鈥?089/鈥媎ia.鈥?007.鈥?227 PubMed
14.Kuziemski K, Specjalski K, Jassem E (2011) Diabetic pulmonary microangiopathy鈥攆act or fiction? Endokrynol Pol 62(2):171鈥?76PubMed
15.Pitocco D, Fuso L, Conte EG, Zaccardi F, Condoluci C, Scavone G, Incalzi RA, Ghirlanda G (2012) The diabetic lung鈥揳 new target organ? Rev Diabet Stud 9(1):23鈥?5. doi:10.鈥?900/鈥婻DS.鈥?012.鈥?.鈥?3 PubMed Central CrossRef PubMed
16.Scano G, Filippelli M, Romagnoli I, Mancini M, Misuri G, Duranti R, Rosi E (2000) Hypoxic and hypercapnic breathlessness in patients with type I diabetes mellitus. Chest 117(4):960鈥?67CrossRef PubMed
17.Galie N, Beghetti M, Gatzoulis MA, Granton J, Berger RMF, Lauer A, Chiossi E, Landzberg M, Invest B (2006) Bosentan therapy in patients with Eisenmenger syndrome鈥攁 multicenter, double-blind, randomized, placebo-controlled study. Circulation 114(1):48鈥?4. doi:10.鈥?161/鈥婥irculationaha.鈥?06.鈥?30715 CrossRef PubMed
18.Sitbon O, Gressin V, Speich R, Macdonald PS, Opravil M, Cooper DA, Fourme T, Humbert M, Delfraissy JF, Simonneau G (2004) Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 170(11):1212鈥?217. doi:10.鈥?164/鈥媟ccm.鈥?00404-445OC CrossRef PubMed
19.Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J, Niedermeyer J, Winkler J (2005) Bosentan therapy for portopulmonary hypertension. Eur Respir J 25(3):502鈥?08. doi:10.鈥?183/鈥?9031936.鈥?5.鈥?0080804 CrossRef PubMed
20.Rafnsson A, Bohm F, Settergren M, Gonon A, Brismar K, Pernow J (2012) The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial. Diabetologia 55(3):600鈥?07. doi:10.鈥?007/鈥媠00125-011-2415-y CrossRef PubMed
21.Hauber HP, Blaukovitsch M (2010) Current and future treatment options in idiopathic pulmonary fibrosis. Inflamm Allergy Drug Targets 9(3):158鈥?72CrossRef PubMed
22.Cosentino F, Luscher TF (1998) Endothelial dysfunction in diabetes mellitus. J Cardiovasc Pharmacol 32(Suppl 3):S54鈥揝61PubMed
23.Eleftheriadis T, Antoniadi G, Pissas G, Liakopoulos V, Stefanidis I (2013) The renal endothelium in diabetic nephropathy. Ren Fail 35(4):592鈥?99. doi:10.鈥?109/鈥?886022X.鈥?013.鈥?73836 CrossRef PubMed
24.Eringa EC, Serne EH, Meijer RI, Schalkwijk CG, Houben AJ, Stehouwer CD, Smulders YM, van Hinsbergh VW (2013) Endothelial dysfunction in (pre)diabetes: characteristics, causative mechanisms and pathogenic role in type 2 diabetes. Rev Endocr Metab Disord 14(1):39鈥?8. doi:10.鈥?007/鈥媠11154-013-9239-7 CrossRef PubMed
25.Feener EP, King GL (2001) Endothelial dysfunction in diabetes mellitus: role in cardiovascular disease. Heart Fail Monit 1(3):74鈥?2PubMed
26.Lee SH, Channick RN (2005) Endothelin antagonism in pulmonary arterial hypertension. Semin Respir Crit Care Med 26(4):402鈥?08. doi:10.鈥?055/鈥媠-2005-916155 CrossRef PubMed
27.Shao D, Park JE, Wort SJ (2011) The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension. Pharmacol Res 63(6):504鈥?11. doi:10.鈥?016/鈥媕.鈥媝hrs.鈥?011.鈥?3.鈥?03 CrossRef PubMed
28.Arison RN, Ciaccio EI, Glitzer MS, Cassaro JA, Pruss MP (1967) Light and electron microscopy of lesions in rats rendered diabetic with streptozotocin. Diabetes 16(1):51鈥?6CrossRef PubMed
29.Hasanein P, Shahidi S (2010) Effects of combined treatment with vitamins C and E on passive avoidance learning and memory in diabetic rats. Neurobiol Learn Mem 93(4):472鈥?78. doi:10.鈥?016/鈥媕.鈥媙lm.鈥?010.鈥?1.鈥?04 CrossRef PubMed
30.de Souza LF, Barreto F, da Silva EG, Andrades ME, Guimaraes EL, Behr GA, Moreira JC, Bernard EA (2007) Regulation of LPS stimulated ROS production in peritoneal macrophages from alloxan-induced diabetic rats: involvement of high glucose and PPARgamma. Life Sci 81(2):153鈥?59. doi:10.鈥?016/鈥媕.鈥媗fs.鈥?007.鈥?4.鈥?35 CrossRef PubMed
31.Ghorbani A, Omrani GR, Hadjzadeh MA, Varedi M (2013) Proinsulin C-peptide inhibits lipolysis in diabetic rat adipose tissue through phosphodiestrase-3B enzyme. Horm Metab Res 45(3):221鈥?25. doi:10.鈥?055/鈥媠-0032-1323764 PubMed
32.Ghorbani A, Varedi M, Hadjzadeh MA, Omrani GH (2010) Type-1 diabetes induces depot-specific alterations in adipocyte diameter and mass of adipose tissues in the rat. Exp Clin Endocrinol Diabetes 118(7):442鈥?48. doi:10.鈥?055/鈥媠-0030-1247566 CrossRef PubMed
33.Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95(2):351鈥?58CrossRef PubMed
34.Sedlak J, Lindsay RH (1968) Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman鈥檚 reagent. Anal Biochem 25(1):192鈥?05CrossRef PubMed
35.Sun Y, Oberley LW, Li Y (1988) A simple method for clinical assay of superoxide dismutase. Clin Chem 34(3):497鈥?00PubMed
36.Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-Delta Delta C) method. Methods 25(4):402鈥?08. doi:10.鈥?006/鈥媘eth.鈥?001.鈥?262 CrossRef PubMed
37.Guerci B, Bohme P, Kearney-Schwartz A, Zannad F, Drouin P (2001) Endothelial dysfunction and type 2 diabetes. Part 2: altered endothelial function and the effects of treatments in type 2 diabetes mellitus. Diabetes Metab 27(4 Pt 1):436鈥?47PubMed
38.Sarman B, Toth M, Somogyi A (1998) Role of endothelin-1 in diabetes mellitus. Diabetes Metab Rev 14(2):171鈥?75CrossRef PubMed
39.Ergul A (2011) Endothelin-1 and diabetic complications: focus on the vasculature. Pharmacol Res 63(6):477鈥?82. doi:10.鈥?016/鈥媕.鈥媝hrs.鈥?011.鈥?1.鈥?12 CrossRef PubMed
40.Comellas AP, Briva A (2009) Role of endothelin-1 in acute lung injury. Transl Res 153(6):263鈥?71. doi:10.鈥?016/鈥媕.鈥媡rsl.鈥?009.鈥?2.鈥?07 PubMed Central CrossRef PubMed
41.Ross B, D鈥橭rleans-Juste P, Giaid A (2010) Potential role of endothelin-1 in pulmonary fibrosis: from the bench to the clinic. Am J Respir Cell Mol Biol 42(1):16鈥?0. doi:10.鈥?165/鈥媟cmb.鈥?009-0175TR CrossRef PubMed
42.Schneider MP, Boesen EI, Pollock DM (2007) Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol 47:731鈥?59. doi:10.鈥?146/鈥媋nnurev.鈥媝harmtox.鈥?7.鈥?20505.鈥?05134 PubMed Central CrossRef PubMed
43.Cardillo C, Campia U, Bryant MB, Panza JA (2002) Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation 106(14):1783鈥?787CrossRef PubMed
44.McAuley DF, Nugent AG, McGurk C, Maguire S, Hayes JR, Johnston GD (2000) Vasoconstriction to endogenous endothelin-1 is impaired in patients with Type II diabetes mellitus. Clin Sci 99(3):175鈥?79. doi:10.鈥?042/鈥婥s20000005 CrossRef PubMed
45.Zhou Y, Mitra S, Varadharaj S, Parinandi N, Zweier JL, Flavahan NA (2006) Increased expression of cyclooxygenase-2 mediates enhanced contraction to endothelin ETA receptor stimulation in endothelial nitric oxide synthase knockout mice. Circ Res 98(11):1439鈥?445. doi:10.鈥?161/鈥?1.鈥婻ES.鈥?000224120.鈥?2792.鈥?0 CrossRef PubMed
46.Climent B, Fernandez N, Sanz E, Sanchez A, Monge L, Garcia-Villalon AL, Dieguez G (2005) Enhanced response of pig coronary arteries to endothelin-1 after ischemia-reperfusion. Role of endothelin receptors, nitric oxide and prostanoids. Eur J Pharmacol 524(1鈥?):102鈥?10. doi:10.鈥?016/鈥媕.鈥媏jphar.鈥?005.鈥?9.鈥?02 CrossRef PubMed
47.Fonseca C, Abraham D, Renzoni EA (2011) Endothelin in pulmonary fibrosis. Am J Respir Cell Mol Biol 44(1):1鈥?0. doi:10.鈥?165/鈥媟cmb.鈥?009-0388TR CrossRef PubMed
48.Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, Rubin LJ (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358(9288):1119鈥?123. doi:10.鈥?016/鈥婼0140-6736(01)06250-X CrossRef PubMed
49.Prakash A, Perry CM (2002) Bosentan. Am J Cardiovasc Drugs 2(5):335鈥?43 (discussion 343)CrossRef PubMed
50.Araz O, Demirci E, Yilmazel Ucar E, Calik M, Pulur D, Karaman A, Yayla M, Altun E, Halici Z, Akgun M (2013) Comparison of reducing effect on lung injury of dexamethasone and bosentan in acute lung injury: an experimental study. Multidiscip Respir Med 8(1):74. doi:10.鈥?186/鈥?049-6958-8-74 PubMed Central CrossRef PubMed
51.Galie N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, Chiossi E, Kusic-Pajic A, Simonneau G (2008) Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371(9630):2093鈥?100. doi:10.鈥?016/鈥婼0140-6736(08)60919-8 CrossRef PubMed
52.Elmarakby AA, Sullivan JC (2012) Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther 30(1):49鈥?9. doi:10.鈥?111/鈥媕.鈥?755-5922.鈥?010.鈥?0218.鈥媥 CrossRef PubMed
53.Navarro-Gonzalez JF, Jarque A, Muros M, Mora C, Garcia J (2009) Tumor necrosis factor-alpha as a therapeutic target for diabetic nephropathy. Cytokine Growth Factor Rev 20(2):165鈥?73. doi:10.鈥?016/鈥媕.鈥媍ytogfr.鈥?009.鈥?2.鈥?05 CrossRef PubMed
54.Nishimura M, Obayashi H, Mizuta I, Hara H, Adachi T, Ohta M, Tegoshi H, Fukui M, Hasegawa G, Shigeta H, Kitagawa Y, Nakano K, Kaji R, Nakamura N (2003) TNF, TNF receptor type 1, and allograft inflammatory factor-1 gene polymorphisms in Japanese patients with type 1 diabetes. Hum Immunol 64(2):302鈥?09CrossRef PubMed
55.Gonzalez-Clemente JM, Mauricio D, Richart C, Broch M, Caixas A, Megia A, Gimenez-Palop O, Simon I, Martinez-Riquelme A, Gimenez-Perez G, Vendrell J (2005) Diabetic neuropathy is associated with activation of the TNF-alpha system in subjects with type 1 diabetes mellitus. Clin Endocrinol 63(5):525鈥?29. doi:10.鈥?111/鈥媕.鈥?365-2265.鈥?005.鈥?2376.鈥媥 CrossRef
56.Yoshida A, Yoshida S, Khalil AK, Ishibashi T, Inomata H (1998) Role of NF-kappa B-mediated interleukin-8 expression in intraocular neovascularization. Invest Ophthalmol Vis Sci 39(7):1097鈥?106PubMed
57.Gupta S, Gambhir JK, Kalra O, Gautam A, Shukla K, Mehndiratta M, Agarwal S, Shukla R (2013) Association of biomarkers of inflammation and oxidative stress with the risk of chronic kidney disease in Type 2 diabetes mellitus in North Indian population. J Diabetes Complications 27(6):548鈥?52. doi:10.鈥?016/鈥媕.鈥媕diacomp.鈥?013.鈥?7.鈥?05 CrossRef PubMed
58.Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Li Q, Tomiyama H, Kobayashi Y, Noda A, Sasamata M, Shibasaki M (2013) Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol 715(1鈥?):246鈥?55. doi:10.鈥?016/鈥媕.鈥媏jphar.鈥?013.鈥?5.鈥?14 CrossRef PubMed
59.Bowen T, Jenkins RH, Fraser DJ (2013) MicroRNAs, transforming growth factor beta-1, and tissue fibrosis. J Pathol 229(2):274鈥?85. doi:10.鈥?002/鈥媝ath.鈥?119 CrossRef PubMed
60.Samarakoon R, Overstreet JM, Higgins PJ (2013) TGF-beta signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities. Cell Signal 25(1):264鈥?68. doi:10.鈥?016/鈥媕.鈥媍ellsig.鈥?012.鈥?0.鈥?03 PubMed Central CrossRef PubMed
61.Gao Y, Xu X, Ding K, Liang Y, Jiang D, Dai H (2013) Rapamycin inhibits transforming growth factor beta1-induced fibrogenesis in primary human lung fibroblasts. Yonsei Med J 54(2):437鈥?44. doi:10.鈥?349/鈥媦mj.鈥?013.鈥?4.鈥?.鈥?37 PubMed Central CrossRef PubMed
62.Song X, Liu W, Xie S, Wang M, Cao G, Mao C, Lv C (2013) All-trans retinoic acid ameliorates bleomycin-induced lung fibrosis by downregulating the TGF-beta1/Smad3 signaling pathway in rats. Lab Invest 93(11):1219鈥?231. doi:10.鈥?038/鈥媗abinvest.鈥?013.鈥?08 CrossRef PubMed
63.El Gazaerly H, Elbardisey DM, Eltokhy HM, Teaama D (2013) Effect of transforming growth factor Beta 1 on wound healing in induced diabetic rats. Int J Health Sci (Qassim) 7(2):160鈥?72CrossRef
64.Sipal S, Halici Z, Kiki I, Polat B, Albayrak A, Albayrak F, Karakus E, Aksak S, Ozturk B, Gundogdu C (2012) Comparative study of three angiotensin II type 1 receptor antagonists in preventing liver fibrosis in diabetic rats: stereology, histopathology, and electron microscopy. J Mol Histol 43(6):723鈥?35. doi:10.鈥?007/鈥媠10735-012-9441-z CrossRef PubMed
65.Halici Z, Bilen H, Albayrak F, Uyanik A, Cetinkaya R, Suleyman H, Keles ON, Unal B (2009) Does telmisartan prevent hepatic fibrosis in rats with alloxan-induced diabetes? Eur J Pharmacol 614(1鈥?):146鈥?52. doi:10.鈥?016/鈥媕.鈥媏jphar.鈥?009.鈥?4.鈥?42 CrossRef PubMed
66.Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L (2001) Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol 133(5):687鈥?94. doi:10.鈥?038/鈥媠j.鈥媌jp.鈥?704131 PubMed Central CrossRef PubMed
67.Sharma K, Ix JH, Mathew AV, Cho M, Pflueger A, Dunn SR, Francos B, Sharma S, Falkner B, McGowan TA, Donohue M, Ramachandrarao S, Xu R, Fervenza FC, Kopp JB (2011) Pirfenidone for diabetic nephropathy. J Am Soc Nephrol 22(6):1144鈥?151. doi:10.鈥?681/鈥婣SN.鈥?010101049 PubMed Central CrossRef PubMed
68.Shepler B, Nash C, Smith C, Dimarco A, Petty J, Szewciw S (2012) Update on potential drugs for the treatment of diabetic kidney disease. Clin Ther 34(6):1237鈥?246. doi:10.鈥?016/鈥媕.鈥媍linthera.鈥?012.鈥?4.鈥?26 CrossRef PubMed
69.Obrosova IG (2005) Increased sorbitol pathway activity generates oxidative stress in tissue sites for diabetic complications. Antioxid Redox Signal 7(11鈥?2):1543鈥?552. doi:10.鈥?089/鈥媋rs.鈥?005.鈥?.鈥?543 CrossRef PubMed
70.Vincent AM, Russell JW, Low P, Feldman EL (2004) Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev 25(4):612鈥?28. doi:10.鈥?210/鈥婨r.鈥?003-0019 CrossRef PubMed
71.Ziegler D, Sohr CGH, Nourooz-Zadeh J (2004) Oxidative stress and antioxidant defense in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy. Diabetes Care 27(9):2178鈥?183. doi:10.鈥?337/鈥媎iacare.鈥?7.鈥?.鈥?178 CrossRef PubMed
72.Pennathur S, Heinecke JW (2007) Oxidative stress and endothelial dysfunction in vascular disease. Curr Diab Rep 7(4):257鈥?64CrossRef PubMed
73.Wen Y, Skidmore JC, Porter-Turner MM, Rea CA, Khokher MA, Singh BM (2002) Relationship of glycation, antioxidant status and oxidative stress to vascular endothelial damage in diabetes. Diabetes Obes Metab 4(5):305鈥?08CrossRef PubMed
74.Uyanik A, Unal D, Uyanik MH, Halici Z, Odabasoglu F, Altunkaynak ZB, Cadirci E, Keles M, Gundogdu C, Suleyman H, Bayir Y, Albayrak M, Unal B (2010) The effects of polymicrobial sepsis with diabetes mellitus on kidney tissues in ovariectomized rats. Ren Fail 32(5):592鈥?02. doi:10.鈥?109/鈥?886022100375947鈥? CrossRef PubMed
75.Suys B, de Beeck LO, Rooman R, Kransfeld S, Heuten H, Goovaerts I, Vrints C, de Wolf D, Matthys D, Manuel-y-Keenoy B (2007) Impact of oxidative stress on the endothelial dysfunction of children and adolescents with type 1 diabetes mellitus: protection by superoxide dismutase? Pediatr Res 62(4):456鈥?61. doi:10.鈥?203/鈥婸DR.鈥?b013e318142581a鈥?/span> CrossRef PubMed
76.Goyal R, Singhai M, Faizy AF (2011) Glutathione peroxidase activity in obese and nonobese diabetic patients and role of hyperglycemia in oxidative stress. J Midlife Health 2(2):72鈥?6. doi:10.鈥?103/鈥?976-7800.鈥?2529 PubMed Central PubMed
77.Likidlilid A, Patchanans N, Poldee S, Peerapatdit T (2007) Glutathione and glutathione peroxidase in type 1 diabetic patients. J Med Assoc Thai 90(9):1759鈥?767PubMed
78.Yayla M, Halici Z, Unal B, Bayir Y, Akpinar E, Gocer F (2014) Protective effect of Et-1 receptor antagonist bosentan on paracetamol induced acute liver toxicity in rats. Eur J Pharmacol 726C:87鈥?5. doi:10.鈥?016/鈥媕.鈥媏jphar.鈥?014.鈥?1.鈥?22 CrossRef
79.Halici Z, Bilen H, Albayrak F, Uyanik A, Cetinkaya R, Suleyman H, Keles ON, Unal B (2009) Does telmisartan prevent hepatic fibrosis in rats with alloxan-induced diabetes? Eur J Pharmacol 614(1鈥?):146鈥?52. doi:10.鈥?016/鈥婮.鈥婨jphar.鈥?4.鈥?42 CrossRef PubMed
80.Albayrak A, Uyanik MH, Odabasoglu F, Halici Z, Uyanik A, Bayir Y, Albayrak F, Albayrak Y, Polat B, Suleyman H (2011) The effects of diabetes and/or polymicrobial sepsis on the status of antioxidant enzymes and pro-inflammatory cytokines on heart, liver, and lung of ovariectomized rats. J Surg Res 169(1):67鈥?5. doi:10.鈥?016/鈥媕.鈥媕ss.鈥?009.鈥?9.鈥?55 CrossRef PubMed
81.Nakhjavani M, Esteghamati A, Nowroozi S, Asgarani F, Rashidi A, Khalilzadeh O (2010) Type 2 diabetes mellitus duration: an independent predictor of serum malondialdehyde levels. Singapore Med J 51(7):582鈥?85PubMed
82.Reis JS, Veloso CA, Volpe CM, Fernandes JS, Borges EA, Isoni CA, Dos Anjos PM, Nogueira-Machado JA (2012) Soluble RAGE and malondialdehyde in type 1 diabetes patients without chronic complications during the course of the disease. Diab Vasc Dis Res 9(4):309鈥?14. doi:10.鈥?177/鈥?479164111436316鈥?/span> CrossRef PubMed
83.Singh G, Sharma B, Jaggi AS, Singh N (2014) Efficacy of bosentan, a dual ETA and ETB endothelin receptor antagonist, in experimental diabetes induced vascular endothelial dysfunction and associated dementia in rats. Pharmacol Biochem Behav 124:27鈥?5. doi:10.鈥?016/鈥媕.鈥媝bb.鈥?014.鈥?5.鈥?02 CrossRef PubMed
84.Jiang JH, Yuen V, Xiang H, McNeill JH (2006) Improvement in cardiac function of diabetic rats by bosentan is not associated with changes in the activation of PKC isoforms. Mol Cell Biochem 282(1鈥?):177鈥?85. doi:10.鈥?007/鈥婼11010-006-1926-1 CrossRef PubMed
85.Sachidanandam K, Portik-Dobos V, Kelly-Cobbs AI, Ergul A (2010) Dual endothelin receptor antagonism prevents remodeling of resistance arteries in diabetes. Can J Physiol Pharm 88(6):616鈥?21. doi:10.鈥?139/鈥媃10-034 CrossRef - 作者单位：A. Cayir (1)
R. A. Ugan (2)
A. Albayrak (2)
D. Kose (2)
E. Akpinar (2)
Y. Cayir (3)
H. T. Atmaca (4)
Z. Bayraktutan (5)
M. Kara (6)
1. Department of Pediatric Endocrinology, Erzurum Regional Education and Research Hospital, 25100, Erzurum, Turkey
2. Department of Pharmacology, Faculty of Medicine, Ataturk University, Erzurum, Turkey
3. Department of Family Medicine, Faculty of Medicine, Ataturk University, Erzurum, Turkey
4. Department of Pathology, Faculty of Veterinary, Kirikkale University, Kirikkale, Turkey
5. Department of Biochemistry, Erzurum Regional Education and Research Hospital, Erzurum, Turkey
6. Department of Pediatry, Faculty of Medicine, Ataturk University, Erzurum, Turkey - 刊物类别：Medicine/Public Health, general; Endocrinology; Metabolic Diseases;
- 刊物主题：Medicine/Public Health, general; Endocrinology; Metabolic Diseases;
- 出版者：Springer International Publishing
- ISSN：1720-8386
文摘
Purpose The aim of this study is to show the effect of a new mechanism on endothelin (ET) receptors in the physiopathology of diabetes-related pulmonary injury. We tested the hypothesis that dual ET-1 receptor antagonism via bosentan can reverse diabetes-induced lung injury.